Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
Saved in:
| Title: | Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor. |
|---|---|
| Authors: | Turpin A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Lille University Hospital, F-59000, Lille, France., Delliaux C; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Parent P; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Lille University Hospital, F-59000, Lille, France., Chevalier H; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Medical Oncology, Centre Oscar Lambret, 3, rue Frederic Combemale, 59000, Lille, France., Escudero-Iriarte C; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Bonardi F; University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, F-59000, Lille, France., Vanpouille N; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Flourens A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Querol J; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Carnot A; Department of Medical Oncology, Centre Oscar Lambret, 3, rue Frederic Combemale, 59000, Lille, France., Leroy X; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Institut de Pathologie, CHU Lille, Avenue Oscar Lambret, F-59000, Lille, France., Herranz N; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Lanel T; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Institut de Pathologie, CHU Lille, Avenue Oscar Lambret, F-59000, Lille, France., Villers A; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France., Olivier J; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France., Touzet H; University Lille, CNRS, Centrale Lille, UMR 9189 CRIStAL, F-59000, Lille, France., de Launoit Y; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Tian TV; Vall d'Hebron Institute of Oncology (VHIO), 08035, Barcelona, Spain., Duterque-Coquillaud M; University Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France. martine.duterque@cnrs.fr. |
| Source: | British journal of cancer [Br J Cancer] 2023 Dec; Vol. 129 (12), pp. 1903-1914. Date of Electronic Publication: 2023 Oct 24. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
